Exploring the Efficacy and Safety of New Treatment for Malignant Mesothelioma

The National Cancer Center, China, has launched a Phase 1, 2 clinical trial to investigate the effectiveness and safety of a new treatment combination for patients with malignant mesothelioma, a rare and aggressive cancer. The trial, led by principal investigator Puyuan Xing, MD, will test the combination of Iparomlimab and Tuvonralimab, a dual-function antibody targeting PD-1 and CTLA-4, with chemotherapy. The study aims to explore a potentially more effective and safer option for patients with limited treatment success.

Key Takeaways:

• The clinical trial will involve a total of 55 participants, with 6 patients initially receiving the treatment combination in Phase Ib to assess safety.
• If no major safety issues arise, the study will proceed to Phase II, where 49 patients will be enrolled to evaluate treatment effectiveness.
• The study includes two groups for first-line treatment and second-line treatment to assess the efficacy of the new treatment combination.
• Qilu Pharmaceutical Co., Ltd., and multiple cancer hospitals are collaborating with the National Cancer Center, China, on this trial.
• The study aims to investigate a potentially more effective and safer treatment option for patients with malignant mesothelioma.

Statistics:

• 6 patients will receive the treatment combination in Phase Ib to assess safety.
• 49 patients will be enrolled in Phase II to evaluate treatment effectiveness.
• The study includes two groups for first-line treatment and second-line treatment.
• The clinical trial is listed on ClinicalTrials.gov with the identifier NCT07131345.

Sources:

• ClinicalTrials.gov
• Contify.com